COPD (chronic obstructive pulmonary disease) is a group of progressive lung diseases typically characterised by chronic bronchitis and emphysema, which cause irreversible airflow limitation and inflammation in the airways.1
Although COPD is most commonly caused by long-term smoking, a substantive burden of the disease is due to occupational exposure to harmful agents, and genetic conditions such as congenital α1-antitrypsin deficiency.1
A global problem
COPD is not only a major health concern for governments and healthcare bodies, it’s also a leading contributor of disability and reduced quality of life in communities around the world. Often undiagnosed until chronic symptoms appear, the world health organisation (WHO) estimates that right now, over 65 million people worldwide are living with moderate to severe COPD.2
Affecting individuals and families, COPD is often associated with tobacco smoking, but 1 in 5 patients diagnosed with COPD have never smoked.3,4
For patients who become hospitalised with acute exacerbations, close to 20% are readmitted within 30 days,5 with each hospitalisation placing a tremendous burden on patients and their families.
An economic problem
As the third leading cause of death worldwide, COPD is estimated to claim over 3 million lives globally every year. And as the population ages, this is expected to increase by 30% over the next decade.2
This growing number of patients creates heavy economic burdens. The annual cost on our healthcare system so far is already:
- €38.6 billion in Europe1
- $USD49.9 billion in the United States1
- $AUD929 million in Australia.6
Given this significant impact, hospitals, insurance companies, care providers and patients are all looking for better solutions for the long-term care and management of COPD.
By understanding the problems caused by COPD and what ResMed’s intelligent non-invasive ventilation solutions can do, you can help create healthier communities and reduce the costs to healthcare.
Seeing the bigger COPD picture